| Followers | 425 |
| Posts | 20207 |
| Boards Moderated | 1 |
| Alias Born | 02/22/2010 |
Wednesday, May 31, 2017 1:33:46 AM
$MRUS at 19 now we getting 6 pps (25%) off what $INCY paid for investment. Wedbush has target now at 32
http://www.bizjournals.com/philadelphia/news/2016/12/21/incyte-merus-netherlands-antibody-bispecific-tech.html?ana=yahoo
and presenting at ASCO. will report the full dataset from the Phase 1 study of HER2 × HER3 MCLA-128 http://247wallst.com/healthcare-business/2017/05/27/top-presentations-to-look-for-at-asco/
http://phoenix.corporate-ir.net/phoenix.zhtml?c=254206&p=irol-newsArticle_print&ID=2263434
The company said it will initiate the Phase 2 clinical trial in the second half of 2017, exploring two metastatic breast cancer populations, namely HER2-positive patients and hormone receptor-positive/HER2-low patients. https://www.benzinga.com/general/biotech/17/05/9488518/the-most-notable-abstracts-released-ahead-of-asco-2017
http://www.bizjournals.com/philadelphia/news/2016/12/21/incyte-merus-netherlands-antibody-bispecific-tech.html?ana=yahoo
and presenting at ASCO. will report the full dataset from the Phase 1 study of HER2 × HER3 MCLA-128 http://247wallst.com/healthcare-business/2017/05/27/top-presentations-to-look-for-at-asco/
http://phoenix.corporate-ir.net/phoenix.zhtml?c=254206&p=irol-newsArticle_print&ID=2263434
The company said it will initiate the Phase 2 clinical trial in the second half of 2017, exploring two metastatic breast cancer populations, namely HER2-positive patients and hormone receptor-positive/HER2-low patients. https://www.benzinga.com/general/biotech/17/05/9488518/the-most-notable-abstracts-released-ahead-of-asco-2017
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
